Plain-English translation of NCT02760407 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid arthritis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested olokizumab, a new injectable medication designed to help people with moderate to severe rheumatoid arthritis whose disease wasn't adequately controlled by methotrexate. Researchers compared this medication given at two different dosing schedules against both a placebo and an existing arthritis drug called adalimumab to see which approach worked best at reducing joint inflammation and improving function.
Many people with rheumatoid arthritis don't get good enough symptom control from methotrexate alone, and they need additional treatment options. This trial was designed to see whether this medication could be an effective and safe add-on therapy for those patients.
Participants attended a 4-week screening visit to confirm they were eligible, then received study treatment for 24 weeks. Depending on which group they were assigned to, they received either the new medication by injection every 2 weeks, every 4 weeks (alternating with placebo injections), an existing arthritis medication every 2 weeks, or placebo injections every 2 weeks—all while continuing their methotrexate. They returned to the study site at least every 2 weeks for check-ups and assessments of how well their joints were doing, and continued in a follow-up safety period through week 44.
AI-generated summary from trial data · Oct 5, 2026 · Not medical advice
United States